Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZINBRYTA is a monoclonal antibody approved by the FDA in May 2016 for an undisclosed indication. As a mAb therapeutic, it works through targeted immune modulation via injection. The specific indication and mechanism of action are not provided in the available data.
Peak
Product is at peak commercial stage with moderate competitive pressure (30%), suggesting stable but not growth-phase headcount expansion opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ZINBRYTA is generating 255 linked job openings with demand concentrated in leadership, manufacturing, and commercial functions at peak lifecycle. Working on this product offers exposure to mature immunology therapeutics commercialization and quality systems management within a Biogen portfolio.
DirectorDirector Corporate Strategy
Worked on ZINBRYTA at Biogen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.